CClinicalTrials.gg
CompletedNCT03763409Updated Dec 6, 2018

Losartan and Emotional Memory

An interventional study of Losartan Potassium and placebo in Memory and Learning, sponsored by University of Oxford. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-06.

Sponsored by University of Oxford · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2018, registered Nov 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study explores the effects of single-dose losartan (50mg) versus identical placebo capsule on emotional memory and learning in healthy volunteers.

Read the detailed description

The commonly prescribed antihypertensive drug losartan (brand name: Cozaar; UK licensed for 20 years) targets the renin-angiotensin system - a hormone system regulating blood pressure - by acting as an angiotensin receptor antagonist. In particular, the drug prevents a docking of the protein angiotensin IV to AT1 receptors, which leads to a dilation if vessels and a reduction in blood pressure. However, the increase in free angiotensin IV has also been associated with an increase in synaptic plasticity, the cellular mechanism involved in learning and memory. As such, losartan appears to have cognition-enhancing properties, in a way that a single dose of 50mg improves prospective memory in healthy humans. However, preliminary pre-clinical results also suggest that a single injection of the drug improves fear extinction in rodents, which is the equivalent to human cognitive-behavioural therapy for anxiety disorders. Furthermore, compared to other antihypertensive drugs, regular losartan treatment appears to prevent the development of post-traumatic stress disorder symptoms following trauma exposition. Such results suggest that the renin-angiotensin system plays a key role in the development and extinction of anxiety, and that adding losartan to cognitive-behavioural therapy for anxiety in humans might have synergistic effects. However, it remains to be clarified what the basic effects of this drug on emotional information processing in humans are to identify mechanisms by which it may improve psychological treatments.

In this study, the key neuropsychological effects of probing the renin-angiotensin system on emotional information processing and learning will be investigated. In a double-blind, randomised between-groups design, 54 healthy volunteers will be randomised to a group receiving a single dose of losartan (50mg) versus placebo. When peak plasma levels are reached, participants will work on a battery of behavioural measures of emotional information processing and learning.

The results from this study will help understand how the renin-angiotensin system affects emotional information processing and learning, and they will help establish a battery of tasks that sensitively respond to such manipulations. Such information will ultimately lead to the development of losartan and similar agents for the more effective and more compact treatment of anxiety disorders.

02

Conditions studied

  • Memory
  • Learning

Keywords

  • anxiety
  • losartan
  • appetitive learning
  • aversive learning
03

In context

Lead sponsor

University of Oxford is the lead sponsor of 794 studies on the registry; 117 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • willing and able to provide informed consent
  • male or Female, aged 18-50
  • body mass index (BMI) of 18-30 kg/m2
  • fluent English skills
  • non- or light-smoker (\< 5 cigarettes a day)

Exclusion criteria

Exclusion Criteria:

  • Female participant who is pregnant or breast-feeding
  • CNS-active medication during the last 6 weeks
  • Current blood pressure or other heart medication (especially aliskiren or beta blockers)
  • Intravascular fluid depletion
  • Past or present DSM-IV axis-I diagnosis or suspected diagnosis (from SCID results at screening)
  • Alcohol or substance abuse
  • First-degree family member with a history of a severe psychiatric disease
  • Impaired liver or kidney function
  • Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Insufficient English skills
  • participated in another study involving CNS-active medication during the last 6 weeks
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    losartan

    50 mg single-dose oral losartan

    Drug: Losartan Potassium

  • Placebo comparator
    placebo

    microcellulose placebo in identical capsule

    Other: placebo

Interventions

  • DrugLosartan Potassium

    active drug

  • Otherplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. aversive and appetitive learning

    a learning task wil assess to what degree participants learn from win versus loss outcomes in different environments

    Time frame: 1 hour after capsule intake

07

Study locations

1 site
  • Department of Psychiatry, University of Oxford
    Oxford, OX37JX, United Kingdom
08

References and documents

Publications

  • Pulcu E, Shkreli L, Holst CG, Woud ML, Craske MG, Browning M, Reinecke A. The Effects of the Angiotensin II Receptor Antagonist Losartan on Appetitive Versus Aversive Learning: A Randomized Controlled Trial. Biol Psychiatry. 2019 Sep 1;86(5):397-404. doi: 10.1016/j.biopsych.2019.04.010. Epub 2019 Apr 17. PubMed 31155138 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03763409
Lead sponsor
University of Oxford
Responsible party
Sponsor
First posted
Dec 4, 2018
Start date
Mar 1, 2018
Primary completion
Sep 28, 2018
Completion
Sep 28, 2018
Last update
Dec 6, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion